Biohaven Pharmaceutical Holding (BHVN) PT Lowered to $144 at Wedbush, Following Earnings
Tweet
Share
E-mail
Get Alerts BHVN Hot Sheet
Price: $10.81 +6.71%
Rating Summary:
17 Buy, 8 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 20 | New: 25
Rating Summary:
17 Buy, 8 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 20 | New: 25
Join SI Premium – FREE
Wedbush analyst Laura Chico lowered the price target on Biohaven Pharmaceutical Holding (NYSE: BHVN) to $144.00 (from $152.00) while maintaining a Outperform rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Upgrades Plains GP Holdings, L.P (PAGP) to Neutral
- Biohaven begins first human trial of brain-penetrant drug BHV-8100
- Tokio Marine Holdings, Inc (8766:JP) (TKOMY) PT Lowered to JPY8,400 at Nomura/Instinet
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
